These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1920306)

  • 41. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis.
    Carette S; Calin A; McCafferty JP; Wallin BA
    Arthritis Rheum; 1989 Feb; 32(2):158-65. PubMed ID: 2645874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term follow-up of technetium articular index in rheumatoid arthritis patients during oral chrysotherapy: evidence of paradoxical behaviour.
    Mathieu A; Pala R; Satta L; Piga M
    Clin Exp Rheumatol; 1988; 6(1):75-8. PubMed ID: 3396250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group.
    Bombardier C; Raboud J
    Control Clin Trials; 1991 Aug; 12(4 Suppl):243S-256S. PubMed ID: 1663860
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention of appearance of radiological lesions in early rheumatoid arthritis: a randomized, single-blind study comparing intra-articular rifamycin with auranofin.
    Caruso I; Santandrea S; Sarzi Puttini P; Montrone F; Boccassini L; Azzolini V; Cazzola M; Dell'Acqua D
    J Int Med Res; 1992 Feb; 20(1):61-77. PubMed ID: 1568521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Auranofin in the treatment of rheumatoid arthritis. Report of 63 cases].
    Tao XL; Dong Y; Zhang NZ
    Zhonghua Nei Ke Za Zhi; 1987 Jul; 26(7):390-3, 444. PubMed ID: 3428027
    [No Abstract]   [Full Text] [Related]  

  • 46. Reconsideration of the effects of methotrexate therapy on radiographic progression in rheumatoid arthritis: comment on the article by Weinblatt et al.
    Roces A; Cantabrana A; Hayek M; Dávila M
    Arthritis Rheum; 1994 Jul; 37(7):1114. PubMed ID: 8024623
    [No Abstract]   [Full Text] [Related]  

  • 47. The effect of auranofin and sulphasalazine therapy on circulating levels of interleukin 6 in rheumatoid arthritis patients.
    Crilly A; Capell HA; Watson J; Madhok R
    Clin Rheumatol; 1995 Sep; 14(5):561-5. PubMed ID: 8549096
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparison of pyritinol and auranofin in the treatment of rheumatoid arthritis. The European Multicentre Study Group.
    Lemmel EM
    Br J Rheumatol; 1993 May; 32(5):375-82. PubMed ID: 8495257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Auranofin. The Pharmacy Department, the Amalgamated Melbourne and Essendon Hospitals.
    Aust Nurses J; 1988 Jun; 17(11):25-6. PubMed ID: 3421870
    [No Abstract]   [Full Text] [Related]  

  • 50. Auranofin: a new drug for rheumatoid arthritis.
    Ann Intern Med; 1987 Apr; 106(4):631-2. PubMed ID: 3826966
    [No Abstract]   [Full Text] [Related]  

  • 51. A stepwise increased dose of auranofin does not influence gastrointestinal side-effects.
    Johannsen F; Brodin U; Emmertsen H; Hansen TM; Faarvang KL; Bugge P; Nielsen GL; Jensen OH; Beyer J; Danneskiold-Samsøe B; Jarner D; Arfeldt E; Krohn L; Nielsen H; Nielsen SE
    Clin Exp Rheumatol; 1997; 15(4):454-5. PubMed ID: 9272314
    [No Abstract]   [Full Text] [Related]  

  • 52. Auranofin, methotrexate, but no placebo: comment on the article by Williams et al.
    Epstein WV; Criswell LA
    Arthritis Rheum; 1992 Nov; 35(11):1406-7. PubMed ID: 1445469
    [No Abstract]   [Full Text] [Related]  

  • 53. Auranofin in rheumatoid arthritis: what variables could affect the clinical response?
    Harth M
    Agents Actions Suppl; 1988; 24():167-77. PubMed ID: 3055876
    [No Abstract]   [Full Text] [Related]  

  • 54. Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples.
    Feeny DH; Torrance GW
    Med Care; 1989 Mar; 27(3 Suppl):S190-204. PubMed ID: 2522159
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methods of assessing the effect of drug therapy on quality of life.
    Ganz PA
    Drug Saf; 1990; 5(4):233-42. PubMed ID: 2198049
    [No Abstract]   [Full Text] [Related]  

  • 56. No firm basis to advocate auranofin in the treatment of juvenile rheumatoid arthritis.
    Criswell LA; Katz PP; Tack BB
    Arthritis Rheum; 1991 Jul; 34(7):934-5. PubMed ID: 1898455
    [No Abstract]   [Full Text] [Related]  

  • 57. Work disability is related to the presence of arthritis and not to a specific diagnosis. Results from a large early arthritis cohort in Argentina.
    Citera G; Ficco HM; Alamino RS; Pra FD; Lencina V; Casalla L; Benegas M; Rillo O; Berman A; Barbaglia AL; Bellomío V; Salinas MH; Alvarez AC; Caeiro F; Marcos J; Salas A; Pellet AC; Techera L; Secco A; Paira S; Ceccato F; Bedrán Z; Soriano ER; Marin J; Salvatierra G; Crespo ME
    Clin Rheumatol; 2015 May; 34(5):929-33. PubMed ID: 25425494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores.
    Ouimet JM; Pope JE; Gutmanis I; Koval J
    Open Rheumatol J; 2008; 2():44-52. PubMed ID: 19088871
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Work disability among two cohorts of women with recent-onset rheumatoid arthritis: a survival analysis.
    Reisine S; Fifield J; Walsh S; Dauser D
    Arthritis Rheum; 2007 Apr; 57(3):372-80. PubMed ID: 17394217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sick leave as a predictor of job loss in patients with chronic arthritis.
    de Buck PD; de Bock GH; van Dijk F; van den Hout WB; Vandenbroucke JP; Vliet Vlieland TP
    Int Arch Occup Environ Health; 2006 Nov; 80(2):160-70. PubMed ID: 16710710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.